<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>医药魔方Info | wechat-feeds</title><link>https://wechat.privacyhide.com/</link><description>传递医药信息，分享资源数据！充电5分钟，吹牛2小时！</description><managingEditor> (hellodword)</managingEditor><pubDate>Sat, 23 Jan 2021 20:55:42 +0800</pubDate><image><url>http://wx.qlogo.cn/mmhead/Q3auHgzwzM7atFjOcqtOTtvWNgsOwlgicIicrbmjDShIKicIH59icHiciaCQ/64</url><title>医药魔方Info | wechat-feeds</title><link>https://wechat.privacyhide.com/</link><width>64</width><height>64</height></image><item><title>信达生物通过配售再融资46.71亿港元</title><link>https://mp.weixin.qq.com/s/Xb8Zg9RuO5umb-DO_sA8CA</link><description></description><content:encoded><![CDATA[信达生物通过配售再融资46.71亿港元]]></content:encoded><pubDate>Sat, 23 Jan 2021 16:11:15 +0800</pubDate></item><item><title>第四批集采现场培训会取消</title><link>https://mp.weixin.qq.com/s/3DkWdRwGjE3mz9mHawBhhw</link><description></description><content:encoded><![CDATA[第四批集采现场培训会取消]]></content:encoded><pubDate>Sat, 23 Jan 2021 16:11:15 +0800</pubDate></item><item><title>君实生物PD-1获FDA快速通道资格</title><link>https://mp.weixin.qq.com/s/V4xn7b7wsKOWuttMUVEvWA</link><description></description><content:encoded><![CDATA[君实生物PD-1获FDA快速通道资格]]></content:encoded><pubDate>Sat, 23 Jan 2021 16:11:15 +0800</pubDate></item><item><title>HIV治疗变革！首款完整长效HIV疗法获FDA批准，每月只需注射1次</title><link>https://mp.weixin.qq.com/s/-6Gn0xMfQTmcYKlg5zDR-w</link><description></description><content:encoded><![CDATA[HIV治疗变革！首款完整长效HIV疗法获FDA批准，每月只需注射1次]]></content:encoded><pubDate>Fri, 22 Jan 2021 17:45:53 +0800</pubDate></item><item><title>降糖效果更优！诺和诺德向FDA递交司美鲁肽新规格上市申请</title><link>https://mp.weixin.qq.com/s/JhdeQykEf03_px2lADG9Zg</link><description></description><content:encoded><![CDATA[降糖效果更优！诺和诺德向FDA递交司美鲁肽新规格上市申请]]></content:encoded><pubDate>Fri, 22 Jan 2021 17:45:53 +0800</pubDate></item><item><title>恒瑞JAK1抑制剂拟纳入突破性疗法，治疗中重度特应性皮炎</title><link>https://mp.weixin.qq.com/s/n6-Yirsyoc1ooOx6A__j8A</link><description></description><content:encoded><![CDATA[恒瑞JAK1抑制剂拟纳入突破性疗法，治疗中重度特应性皮炎]]></content:encoded><pubDate>Fri, 22 Jan 2021 17:45:53 +0800</pubDate></item><item><title>优效于度普利尤单抗，艾伯维乌帕替尼治疗特应性皮炎上市申请拟纳入优先审评</title><link>https://mp.weixin.qq.com/s/O9UvUGgXI3-LJS6tUTD8pg</link><description></description><content:encoded><![CDATA[优效于度普利尤单抗，艾伯维乌帕替尼治疗特应性皮炎上市申请拟纳入优先审评]]></content:encoded><pubDate>Fri, 22 Jan 2021 17:45:53 +0800</pubDate></item><item><title>GSK HIV复方制剂上市申请拟纳入优先审评</title><link>https://mp.weixin.qq.com/s/YQTxQoaocQcsAyvyJvrAxQ</link><description></description><content:encoded><![CDATA[GSK HIV复方制剂上市申请拟纳入优先审评]]></content:encoded><pubDate>Fri, 22 Jan 2021 17:45:53 +0800</pubDate></item><item><title>百济神州「司妥昔单抗」上市申请拟纳入优先审评</title><link>https://mp.weixin.qq.com/s/HdYdLwKE38GbVyFmqQNQWA</link><description></description><content:encoded><![CDATA[百济神州「司妥昔单抗」上市申请拟纳入优先审评]]></content:encoded><pubDate>Fri, 22 Jan 2021 17:45:53 +0800</pubDate></item><item><title>挑战K药失败！默克终止M7824一线治疗NSCLC III期研究</title><link>https://mp.weixin.qq.com/s/WUNG2kO_SqeO8xmb7iYByg</link><description></description><content:encoded><![CDATA[挑战K药失败！默克终止M7824一线治疗NSCLC III期研究]]></content:encoded><pubDate>Thu, 21 Jan 2021 17:08:47 +0800</pubDate></item><item><title>武田高血压新药「美阿沙坦钾片」在中国获批上市</title><link>https://mp.weixin.qq.com/s/nyVaivBbu0rpjDqwTDxdkA</link><description></description><content:encoded><![CDATA[武田高血压新药「美阿沙坦钾片」在中国获批上市]]></content:encoded><pubDate>Thu, 21 Jan 2021 17:08:47 +0800</pubDate></item><item><title>礼来雷莫芦单抗在中国递交上市申请，用于治疗胃癌</title><link>https://mp.weixin.qq.com/s/ufmTqGm2DdoMeFKPk2420Q</link><description></description><content:encoded><![CDATA[礼来雷莫芦单抗在中国递交上市申请，用于治疗胃癌]]></content:encoded><pubDate>Thu, 21 Jan 2021 17:08:47 +0800</pubDate></item><item><title>武田「布格替尼片」中国上市申请获受理，治疗NSCLC</title><link>https://mp.weixin.qq.com/s/FSgm1NXVUNSBSBahe0ETaQ</link><description></description><content:encoded><![CDATA[武田「布格替尼片」中国上市申请获受理，治疗NSCLC]]></content:encoded><pubDate>Thu, 21 Jan 2021 17:08:47 +0800</pubDate></item><item><title>信达生物信迪利单抗+贝伐珠单抗一线治疗肝细胞癌上市申请拟纳入优先审评</title><link>https://mp.weixin.qq.com/s/SChJrZIFOr5SBKthptdAvA</link><description></description><content:encoded><![CDATA[信达生物信迪利单抗+贝伐珠单抗一线治疗肝细胞癌上市申请拟纳入优先审评]]></content:encoded><pubDate>Thu, 21 Jan 2021 17:08:47 +0800</pubDate></item><item><title>奥拉帕利新适应症上市申请拟纳入优先审评，治疗前列腺癌</title><link>https://mp.weixin.qq.com/s/yXePjtm3amaXN9WDc69zeQ</link><description></description><content:encoded><![CDATA[奥拉帕利新适应症上市申请拟纳入优先审评，治疗前列腺癌]]></content:encoded><pubDate>Thu, 21 Jan 2021 17:08:47 +0800</pubDate></item><item><title>拜耳/默沙东抗心衰新药vericiguat获FDA批准上市</title><link>https://mp.weixin.qq.com/s/mc24uto79PhcE5pKGi5rpA</link><description></description><content:encoded><![CDATA[拜耳/默沙东抗心衰新药vericiguat获FDA批准上市]]></content:encoded><pubDate>Wed, 20 Jan 2021 18:48:31 +0800</pubDate></item><item><title>troriluzole治疗轻中度阿尔茨海默症II/III期临床研究失败</title><link>https://mp.weixin.qq.com/s/qeAjaf33EwJivx7VhEH6IA</link><description></description><content:encoded><![CDATA[troriluzole治疗轻中度阿尔茨海默症II/III期临床研究失败]]></content:encoded><pubDate>Wed, 20 Jan 2021 18:48:31 +0800</pubDate></item><item><title>武田罕见病新药soticlestat获CDE拟突破性疗法认定</title><link>https://mp.weixin.qq.com/s/8nmgpum-eTqG7ETYVnw85A</link><description></description><content:encoded><![CDATA[武田罕见病新药soticlestat获CDE拟突破性疗法认定]]></content:encoded><pubDate>Wed, 20 Jan 2021 18:48:31 +0800</pubDate></item><item><title>和铂医药巴托利单抗获CDE拟突破性疗法认定</title><link>https://mp.weixin.qq.com/s/Ehsn9mg3KOOojCLeuUdWIg</link><description></description><content:encoded><![CDATA[和铂医药巴托利单抗获CDE拟突破性疗法认定]]></content:encoded><pubDate>Wed, 20 Jan 2021 18:48:31 +0800</pubDate></item><item><title>阿斯利康呼吸道合胞病毒预防药物nirsevimab获CDE拟突破性疗法认定</title><link>https://mp.weixin.qq.com/s/JjMK80hNRiZ7eWGdefPIFw</link><description></description><content:encoded><![CDATA[阿斯利康呼吸道合胞病毒预防药物nirsevimab获CDE拟突破性疗法认定]]></content:encoded><pubDate>Wed, 20 Jan 2021 18:48:31 +0800</pubDate></item></channel></rss>